Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice

[1]  E. Canning,et al.  A triploblast origin for Myxozoa? , 1998, Nature.

[2]  M. Brenner,et al.  Antitumor responses induced by transgenic expression of CD40 ligand. , 1997, Human gene therapy.

[3]  S. Holland,et al.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  H. Haugen,et al.  Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. , 1997, International immunology.

[5]  R. Flavell,et al.  The Cd40 ligand , 1997, Immunologic research.

[6]  H. Haugen,et al.  Thymic Overexpression of CD40 Ligand Disrupts Normal Thymic Epithelial Organization , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[7]  J. Banchereau,et al.  CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. , 1997, Journal of immunology.

[8]  D. Kohn.  Gene therapy for hematopoietic and immune disorders. , 1996, Bone marrow transplantation.

[9]  J. Suttles,et al.  The many roles of CD40 in cell-mediated inflammatory responses. , 1996, Immunology today.

[10]  A. Müllbacher,et al.  Memory alloreactive cytotoxic T cells do not require costimulation for activation in vitro , 1996, Immunology and cell biology.

[11]  James M. Wilson,et al.  CD40 Ligand-Dependent T Cell Activation: Requirement of B7-CD28 Signaling Through CD40 , 1996, Science.

[12]  R. Noelle,et al.  CD40 and its ligand in host defense. , 1996, Immunity.

[13]  H. Nakauchi,et al.  CD3‐induced apoptosis of CD4+CD8+ thymocytes in the absence of clonotypic T cell antigen receptor , 1996, European journal of immunology.

[14]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[15]  T. Rabbitts,et al.  Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. , 1996, The EMBO journal.

[16]  David A. Williams,et al.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells , 1996, Nature Medicine.

[17]  A. Nienhuis,et al.  Dysregulated expression of GATA-1 following retrovirus-mediated gene transfer into murine hematopoietic stem cells increases erythropoiesis. , 1995, Blood.

[18]  R. Flavell,et al.  An essential role for gp39, the ligand for CD40, in thymic selection , 1995, The Journal of experimental medicine.

[19]  M. Sangster,et al.  Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection. , 1995, Virology.

[20]  W. Leonard,et al.  Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome. , 1995, Journal of hematotherapy.

[21]  S. Proctor,et al.  Non-Hodgkin's Lymphomas , 1994, British Journal of Cancer.

[22]  T. Hogg,et al.  The MHC class I-restricted T cell response to Sendai virus infection in C57BL/6 mice: a single immunodominant epitope elicits an extremely diverse repertoire of T cells. , 1994, International immunology.

[23]  R J Armitage,et al.  Humoral immune responses in CD40 ligand-deficient mice , 1994, The Journal of experimental medicine.

[24]  E. Clark,et al.  Properties of mouse CD40: Cellular distribution of CD40 and B cell activation by monoclonal anti‐mouse CD40 antibodies , 1994, European journal of immunology.

[25]  K.,et al.  Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis , 1994, Journal of virology.

[26]  D. Longo,et al.  Inhibition of human B-cell lymphoma growth by CD40 stimulation. , 1994, Blood.

[27]  F. Ramsdell,et al.  Recombinant CD40 ligand exerts potent biologic effects on T cells. , 1994, Journal of immunology.

[28]  L. Notarangelo,et al.  Defective Expression of CD40 Ligand on T Cells Causes “X‐Linked Immunodeficiency with Hyper‐IgM (HIGM1)” , 1994, Immunological reviews.

[29]  H. Ochs,et al.  The Role of CD40 and its Ligand in the Regulation of the Immune Response , 1994, Immunological reviews.

[30]  L. Lanier,et al.  CD40 preferentially costimulates activation of CD4+ T lymphocytes. , 1994, Journal of immunology.

[31]  Jeffrey A. Ledbetter,et al.  How B and T cells talk to each other , 1994, Nature.

[32]  C. Hannum,et al.  Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. , 1993, Cellular immunology.

[33]  F. Ramsdell,et al.  CD40 ligand is a T cell growth factor , 1993, European journal of immunology.

[34]  M. Daucher,et al.  Factors affecting retroviral vector function and structural integrity. , 1993, Virology.

[35]  J. Mountz,et al.  Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse. , 1993, Journal of immunology.

[36]  I. Pastan,et al.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. , 1992, Science.

[37]  S. Korsmeyer,et al.  bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes , 1991, Cell.

[38]  M. Egerton,et al.  The kinetics of T cell antigen receptor expression by subgroups of CD4+8+ thymocytes: delineation of CD4+8+3(2+) thymocytes as post- selection intermediates leading to mature T cells , 1991, The Journal of experimental medicine.

[39]  I. Magrath,et al.  Non-Hodgkin's Lymphomas , 1990 .

[40]  P. Doherty,et al.  Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. , 1990, Journal of immunology.

[41]  K. Trofatter,et al.  Scanning and transmission electron microscopic studies of complement-mediated lysis and antibody-dependent cell-mediated cytolysis of herpes simplex virus-infected human fibroblasts. , 1980, The American journal of pathology.

[42]  M. R. Mickey,et al.  Lifespan and incidence of cancer and other diseases in selected long-lived inbred mice and their F 1 hybrids. , 1973, Journal of the National Cancer Institute.

[43]  W. G. Hoag.  SPONTANEOUS CANCER IN MICE * , 1963, Annals of the New York Academy of Sciences.

[44]  J. Ihle,et al.  Restoration of lymphocyte function in Janus Kinase 3-deficient mice by retroviral-mediated gene transfer , 1998, Nature Medicine.

[45]  P. Kisielow,et al.  Role of thymic selection in the development of thymic lymphomas in TCR transgenic mice. , 1997, International immunology.

[46]  R. Geha,et al.  X-linked hyper IgM , 1997 .

[47]  J. Banchereau,et al.  CD40-CD40 ligand: a multifunctional receptor-ligand pair. , 1996, Advances in immunology.

[48]  M Vapalahti,et al.  [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.

[49]  H. von Boehmer,et al.  Development and selection of T cells: facts and puzzles. , 1995, Advances in immunology.

[50]  D. Valerio,et al.  Factors affecting the transduction of pluripotent hematopoietic stem cells: long-term expression of a human adenosine deaminase gene in mice. , 1993, Blood.

[51]  A. Vicari,et al.  A novel CD45RA+CD4+ transient thymic subpopulation in MRL-lpr/lpr mice: its relation to non-proliferating CD4-CD8-CD45RA+ tumor cells. , 1993, International immunology.

[52]  M. Egerton,et al.  Intermediates Leading to Mature T Cells , 1991 .

[53]  M. Ashburner.  A Laboratory manual , 1989 .